Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.56 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5379343 | 0.86 | KMT2A (0.86) | MEN1KMT2AGPR119CHRM2CHRM3 | |
| SCHEMBL5371477 | 0.85 | MEN1 (0.78) | MEN1KMT2AGPR119CHRM2CHRM3 | |
| SCHEMBL5374760 | 0.85 | MEN1 (0.78) | MEN1KMT2AGPR119CHRM2CHRM3 | |
| SCHEMBL21494991 | 0.79 | MEN1 (0.61) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL29882233 | 0.79 | MEN1 (0.61) | MEN1KMT2AGPR119USP30KDM4E | |
| SCHEMBL5366572 | 0.79 | SLC6A2 (0.57) | MEN1KMT2ACHRM2CHRM3OPRM1 | |
| SCHEMBL8333913 | 0.78 | MEN1 (0.68) | MEN1KMT2AGPR119USP30STS | |
| SCHEMBL4126039 | 0.77 | MEN1 (0.63) | MEN1KMT2AGPR119USP30CHRM2 | |
| SCHEMBL14655033 | 0.77 | MEN1 (0.63) | MEN1KMT2AGPR119STS | |
| SCHEMBL4541225 | 0.77 | MEN1 (0.64) | MEN1KMT2AGPR119USP30OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176316-B2 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594840-B1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167166-A1 | Amino-piperidine derivatives | OPRL1, GRIA1, GRIN1 | MEN1 4843/4885KMT2A 458/4885GPR119 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.